Startups Stand Out As 13 Biotechs Raise More Than $409m
This article was originally published in Scrip
Venture capital and other private equity investment is booming with 13 recent drug developer financings totaling more than $409m, including 10 startups with some large Series A rounds, showing that the biotechnology industry remains attractive to investors even if the window is closing for initial public offerings in the US.
You may also be interested in...
Private Company Edition: Nine new venture capital mega-rounds include Insilico’s series C, $250m from Blackstone for a CAR-T therapy spinout from Intellia and a $210m series B round for Umoja.
Private Company Edition: Investments by CIRM, the GHIT fund and the European Investment Bank back early-stage science and treatments for neglected diseases. Also, Versant Ventures raises $700m in two funds. In VC deals, Akero raised $70m, Impel NeuroPharma brought in $67.5m.
Pharma and biotech companies raised $4.6bn in the first quarter, exceeding the 2017 quarterly average by $1.4bn. But while the money invested soared, the number of companies funded sank. In public financings, MorphoSys commences US IPO and Mylan sells $1.5bn in notes.